Perfil epidemiológico, clínico e qualidade de vida de crianças afetadas pela hanseníase em um município hiperendêmico do Maranhão

Detalhes bibliográficos
Ano de defesa: 2016
Autor(a) principal: Loiola, Hermaiza Angélica do Bonfim lattes
Orientador(a): AQUINO, Dorlene Maria Cardoso de
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal do Maranhão
Programa de Pós-Graduação: PROGRAMA DE PÓS-GRADUAÇÃO EM ENFERMAGEM/CCBS
Departamento: DEPARTAMENTO DE ENFERMAGEM/CCBS
País: Brasil
Palavras-chave em Português:
Área do conhecimento CNPq:
Link de acesso: http://tedebc.ufma.br:8080/jspui/handle/tede/1438
Resumo: Leprosy is still a serious public health problem in Brazil, still has high rates of leprosy patients under the age of 15 years. The disease can have an impact on the lives of patients, which may affect the quality of life for them. Descriptive study aimed to analyze the epidemiological, clinical and quality of life of children affected by leprosy in a hyperendemic county of Maranhao. The study population consisted of children 5- 14 years old of both sexes, residents in Sao Luis - MA who were in treatment for the disease. For the analysis of the epidemiological and clinical profile, we used a form, and the quality of life, we used the Quality Score of life of child dermatology. 40 cases were analyzed, showed higher frequencies of males (55.0%), aged 12 to 14 years (45.0%), brown color (48.78%), 1st to 4th of education incomplete series of teaching fundamental (62.50%), residents Cohab district (47.50%) and family income above 01 minimum wage (72.50%). As the clinical features were 37.50% of Borderline way, 55.0% were classified as multibacillary operationally and 55.0% had degree of disability equal to 0. When evaluating the quality of life results were: no commitment (25%), mild (18%), moderate (40%) and severe (17%). And domain, it was observed that there was a higher frequency in mild impairment grade (60%) in symptoms and feelings during sleep and treatment.